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Acrylamide  is an important  chemical  with  widespread  industrial  and  other  uses  in  addition  to  gener-
alized  population  exposure  from  certain  cooked  foods.  Previous  rat studies  to  assess  the carcinogenic
potential  of  acrylamide  have  been  carried out  exclusively  in the Fischer  344  rat  with identiﬁcation  of  a
number  of  tumors  amongst  which  mesotheliomas  of  the  tunica  vaginalis  is an  important  tumor  endpoint
in  the classiﬁcation  of  acrylamide  as  a ‘probably  human  carcinogen.  In  a rat  carcinogenicity  study  to
determine  the  human  relevance  of  mesotheliomas  Wistar  Han  rats  were  exposed  to  0,  0.5, 1.5, or  3.0 mgn  utero exposure
europathy
yopathy
arcinogenicity
acrylamide/kg  body  weight/day  in  drinking  water  starting  at gestation  day  6. At  the  end  of  two  years,
mammary  gland  ﬁbroadenomas  in females  and  thyroid  follicular  cell  tumors  in both  sexes  were the  only
tumors  increased  in acrylamide  treated  rats.  These  tumor  endpoints  have  rat-speciﬁc  modes  of  action
suggesting  less  likelihood  of human  cancer  risk than  previously  estimated.  This  study  demonstrates  that
tunica  vaginalis  mesotheliomas  are  strain  speciﬁc  and  not  likely  of  genotoxic  origin.
©  2014  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC. Introduction
Acrylamide (ACR) is a monomer used in the manufacture of
olymers for mining, oil and natural gas processing, paper pro-
uction, waste processing, as well as hospital, laboratory and other
ses. Adverse health effects from industrial emissions and exposure
as been extensively studied Lipworth et al., 2012) and no adverse
ffects have been reported with daily exposure up to 2.1 mg/kg/day
Erdreich and Friedman, 2004). Nevertheless, due to various risk
ssessments, several of the workplace permissible exposure limits
PEL) are under evaluation and may  be lowered considerably.
In addition to industrial exposure to acrylamide, general-
zed population exposure to acrylamide in foodstuffs has been
ocumented (Vesper et al., 2008, 2010). This exposure to ACR
as become a worldwide concern because of its generation in a
ariety of carbohydrate rich foods when cooked at temperatures
xceeding 120 ◦C (Mottram et al., 2002; Friedman, 2003). At
hese temperatures, Maillard reaction of sugars with asparagine
esidues produce acrylamide (Friedman, 2005). The 64th Joint
AO/WHO Expert Committee on Food Additives concluded that
n intake of 1 g/kg body weight/day of ACR could be taken
∗ Corresponding author.
E-mail address: maronpot@earthlink.net (R.R. Maronpot).
ttp://dx.doi.org/10.1016/j.etp.2014.11.009
940-2993/© 2014 The Authors. Published by Elsevier GmbH. This is an open acces
y-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
to represent the average for the general population (JECFA,
2005). The USFDA estimated a mean intake of 0.4 g/day for
ages 2 and up with a 90% conﬁdence limit of >2 g/kg (http://
www.fda.gov/downloads/Food/FoodborneIllnessContaminants/
UCM197239.pdf). This equates to an adult male exposure of
1.4 g/day.
Acrylamide has previously been shown to cause ﬁbroadeno-
mas  of the mammary gland and thyroid gland follicular tumors
in rats (Johnson et al., 1986; Friedman et al., 1995; Beland et al.,
2013). Since these tumor sites have well documented rat-speciﬁc
modes of action (Neumann, 1991; Ben-Jonathan et al., 2008; Alison
et al., 1994), a primary consideration in classiﬁcation of acryla-
mide as a “probable human carcinogen” centers on the induction
of tumors of the tunica vaginalis mesotheliomas (TVMs) in F344
rats (Johnson et al., 1986; Friedman et al., 1995; Beland et al.,
2013). These unique mesotheliomas in acrylamide-treated F344
rats might be considered a potential human health risk if they were
caused by a genotoxic mechanism (Wall, 2005). However, F344
rats have an elevated incidence of TVMs secondary to their known
high spontaneous incidence of Leydig cell tumors (Maronpot et al.,
2009). TVMs found in the acrylamide studies have the same bio-
logical behavior, ultrastructure, and morphology as TVMs found
in control rats, prompting the conclusion that acrylamide accel-
erates the appearance of these background tumors (Damjanov and
Friedman, 1998; Maronpot et al., 2009). It has also been shown that
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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he time-to-tumor and incidence data for TVMs are consistent with
 non-genotoxic mechanism (Maronpot et al., 2009). The mecha-
ism of action of acrylamide induction of TVMs has been elaborated
Shipp et al., 2006).
The EPA calculation of the cancer risk for ACR relies on 2 impor-
ant considerations. The ﬁrst is that acrylamide acts as a mutagen.
e will not discuss this assumption here. Second, that tunica vagi-
alis mesotheliomas (TVMs) are added to thyroid tumors in males
EPA, 2010). Depending on which study is used (Johnson, Fried-
an, or Beland) there are either twice as many TVMs as thyroid
umors or the same number. While the biochemistry supports an
ndocrine mechanism for TVMs, there are no data directly demon-
trating this mechanism (EPA, 2010). In order to clarify the mode
f action of acrylamide induced neoplasms, we sought out a strain
f rats which did not get Leydig cell tumors and had a low level of
ackground TVMs to examine a potential endocrine mode of action.
f acrylamide acted by a genotoxic mode of action, it would nec-
ssarily produce TVMs in a second strain. Wistar Han rats were
elected due to their longevity and low incidence of Leydig cell
umors. We report here the oncogenic response of Wistar Han rats
o orally administered acrylamide. Furthermore, concern has been
xpressed that children might be at higher risk to acrylamide due
o greater dietary acrylamide intake (EPA Science Advisory Board,
008). This parameter was evaluated in the current research by ini-
iating dosing on gestation day 6 in pregnant rats and continued to
ermination of the F1 offspring 2 years later.
. Materials and methods
.1. Study conduct
This study was conducted under GLP guidelines enacted in
ermany in the ‘Chemikaliengesetz’, current edition and OECD
rinciples of Good Laboratory Practice’ Document Nos. 1, 8 and 13
NV/MC/CHEM (98)17, ENV/JM/MONO(99)24, and ENV/JM/MONO
2002)9 and was externally audited. The following guidelines
ere considered: OECD Guideline for the Testing of Chemicals No.
53: Combined chronic toxicity/carcinogenicity studies, adopted
 September 2009; and EC method 8.33. Combined chronic toxi-
ity/carcinogenicity test, 88/303/EEC; Ofﬁcial Journal of European
ommunities, L 133 1988.
.2. Test article
Acrylamide (C3H3NO, CAS no 79-06-1, 1,2-propenamide;
99.9% pure) was  purchased from Sigma Aldrich as a white, odor-
ess, crystalline solid which is stable at room temperature for at
east 2 years. Acrylamide was administered daily in drinking water
t the following doses: 0, 0.5, 1.5 and 3.0 mg/kg/day. Water was
vailable ad libitum. In a separate study, solutions of acrylamide
ere prepared in tap water and evaluated for stability at room
emperature at 6, 13, 20, 27, 41, 55 or 90 test days after prepa-
ation and recovery ranged from 96.9% to 102.6%. In the present
tudy acrylamide solutions were prepared weekly and after con-
entration adjustment for body weight, water bottles were changed
eekly. Aliquots for analysis were taken at the beginning and end
f exposure to determine stability. Acrylamide concentration in the
rinking water was determined at test week 4, 10, 16, 22, 28, 34,
0, 46, 52, 65, 78, and 91. Fig. 1 shows that acrylamide was stable
n the animal cages for the weeks of exposure.
.3. AnimalsSperm positive female Wistar HanTM/RccHanTM:WIST rats were
btained from Harlan Laboratories GmbH, Serumweg 48, 27324
ystrup, Germany in multiple deliveries. At gestation day 6cologic Pathology 67 (2015) 189–195
pregnant dams were provided acrylamide in their drinking water
with exposures continuing in F1 offspring through postnatal day
(pnd) 722. Rats were housed 1 per cage in MACROLON cages
with granulated wood bedding (Brandenburg, 49424 Goldenst-
edt/Arkeburg). Study design is summarized in Table 1. Sixty male
and sixty female rats were selected for the chronic study as well as
5 sentinel animals. Five rats per sex per group were sacriﬁced at 12
months and 18 months. Animal rooms were alternately lit (about
150 lx at approximately 1.50 m room height) and darkened in a 12-
h lighting cycle. Cage side observations were conducted twice per
day during the week and once per day on weekends. Ophthalmo-
logical and auditory examinations were conduct at the interim kills
(12 and 18 months) and at termination.
On day 4 after birth, the weights of the pups were determined.
The size of each litter was adjusted by eliminating extra pups to
yield, as nearly as possible, ﬁve males and ﬁve females per litter. The
remaining animals were allowed to remain with the dams until day
21 of lactation (weaning). On lactation day 21, the F1 animals were
randomized using a computer randomization program to assign the
animals to the subsets within each group.
2.4. Assessment of physical and functional development
Neurological determinations were conducted on 5 rats per
sex per group. Ear opening, eye opening, cleavage of the bal-
anopreputial gland, vaginal opening and upper incisor eruption
were assessed. No signiﬁcant changes were seen in any of these
parameters. Functional tests that included open ﬁeld behavior and
passive avoidance (learning) were conducted at pnd 27 and pas-
sive avoidance (learning) at pnd 34. Functional tests included grip
strength and locomotor activity. No changes were seen in these
parameters.
2.5. Gross necropsy
After 52, 78 or 104 test weeks the respective animals were
sacriﬁced under ether anesthesia by cutting the abdominal aorta,
exsanguinated, weighed, and necropsied under the direction of
a pathologist. For rats that died or were sacriﬁced prematurely,
necropsy examinations were performed immediately after the ani-
mals were found dead or after sacriﬁce. All superﬁcial tissues were
examined visually and by palpation and the cranial roof removed to
allow observation of the brain, pituitary gland and cranial nerves.
After a ventral midline incision and skin reﬂection, all subcutaneous
tissues were examined. The condition of the thoracic and abdom-
inal viscera was noted with due attention to the thymus, lymph
nodes and heart.
The weights of the following organs of all animals assigned
for interim dissection and the ﬁrst 10 surviving main study ani-
mals/sex/group of the main dissection were determined before
ﬁxation: adrenal gland (2), brain, epididymis (2), heart, kid-
ney (2), liver, ovary (2), spleen, testis (2), thyroid including
parathyroid (1), and uterus. Adrenals, gonads and kidneys were
weighed individually and identiﬁed as left or right. Organ
weights of rats that died or were sacriﬁced prematurely were
recorded but not included into the mean value compari-
son.
2.6. Histopathological examination
The following organs of all animals (including deceased or sac-
riﬁced animals) were preserved in 7% buffered formalin: adrenal
(2), aorta abdominalis, bone (os femoris with joint), bone marrow
(os femoris, sternum), brain (cerebrum, cerebellum, medulla/pons),
caecum, clitoral gland (2), coagulating gland with seminal
vesicle, epididymis (2), extraorbital lacrimal gland (2), eye with
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ptic nerve and Harderian gland (2), heart (left and right ventricles,
eptum), intestine, small (duodenum, jejunum, ileum—Swiss roll
ethod), intestine, large (colon, rectum), kidney (2) and ureter, all
acroscopically visible lesions, liver, lungs (with mainstem bronchi
nd bronchioles), lymph node (1, cervical), lymph node (1, mesen-
eric), mammary gland, muscle (skeletal, leg), nasal cavity with
asopharynx, nerve (sciatic), esophagus, ovary (2), pancreas, pitu-
tary, preputial gland (2), prostate, salivary glands (mandibular,
ublingual and parotid gland), seminal vesicle, skin (left ﬂank),
able 1
tudy design and survival and body weight gain at terminal sacriﬁce.
Study design 
Group Dose (mg/kg) Number of rats at sacriﬁce intervals 
12-mo 18-mo 24-mo 
1 0 5M 5M 50M 
5F  5F 50F 
2  0.5 5M 5M 50M 
5F  5F 50F 
3  1.5 5M 5M 50M 
5F  5F 50F 
4  3.0 5M 5M 50M 
5F  5F 50F test item formulation samples.
spinal cord (3 sections), spleen, sternum, stomach (forestom-
ach and glandular stomach), testis (2), thymus, thyroid (2, incl.
parathyroids), tissue masses or tumors (incl. regional lymph nodes),
tongue (incl. base), trachea (incl. larynx), urinary bladder, uterus
(incl. cervix and oviducts), vagina, and Zymbal’s gland. Parathy-
roids cannot always be identiﬁed macroscopically. The eyes were
preserved in Davidson’s and the testes in Bouin’s solution for opti-
mum ﬁxation. Other tissues were ﬁxed in 7% buffered formalin and
stained with hematoxylin and eosin (H&E) or other appropriate
Study parameters
Survival and body weight gain at 24 months
Survival at 24 mo (%) BW gain BW gain vs control
82 549.9 ± 67.6
74 307.0 ± 57.7
72 548.5 ± 55.8 ±0
84 302.8 ± 50.3 −1%
70 528.7 ± 88.6 −4%
78 296.0 ± 59.8 −4%
82 496.0 ± 76.9 −10%
74 264.6 ± 36.8 −14%
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Table  2
Non-neoplastic lesions in target tissues in Wistar Han rat 2-year dose–water carcinogenicity study of acrylamide.
Dose
(mg/kg/da)
Male Female
0 0.5 1.5 3 0 0.5 1.5 3
Tissue and diagnosis
Skeletal muscle (n) (50) (50) (50) (50) (50) (50) (50) (50)
Degeneration 3 12* 18** 11* 0 7* 3 12**
Necrosis 1 2 14** 8* 0 4 2 6*
Inﬂammation 1 10** 18** 7 0 6* 3 11**
Atrophy 0 6* 3 9** 0 3 2 2
Sciatic nerve (n) (50) (50) (50) (50) (50) (50) (50) (50)
Neuropathy 0 3 12** 23** 0 3 1 17**
Spinal cord (n) (50) (50) (50) (50) (50) (50) (50) (50)
Gliosis 0 0 1 9** 0 0 3 3
Degeneration 0 0 1 9** 0 0 2 4
Adrenal gland (n) (50) (50) (50) (50)
Cortical vacuolation 10 13 18 29**
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mn) = Number of tissue samples evaluated.
* p < 0.05.
** p < 0.01.
tains for preparation of microscopic slides. All slides from con-
rol and high dose rats were evaluated as well as rats that died
rematurely.
.7. Statistics
The following statistical methods were used: 2 test, Dunnett’s
est, t-test Fisher exact test, and Peto analysis. These statistical pro-
edures were used for all data.
. Results
.1. Clinical signs (F0 dams) and morphological landmarks (F1
ups)
For F0 generation dams no test article-related clinical signs
r changes in body weight, food consumption, drinking water
onsumption or reproductive parameters from implantation until
eaning were present. No litter values, body weight changes
etween groups, or test article-related physical development alter-
tions in the F1 pups were present during the three-week lactation
eriod. Neurological screening and post-natal functional develop-
ent 21 days after birth were similar among all groups.
.2. Main study mortality
No test article-related deaths were present in rats prior to test
eek 78. By the end of the study at 104 weeks, there was  excel-
ent survival ranging between 70 and 84% with acceptable body
eight gain and no test article-related effect on mortality/survival
mong any of the treated groups and the controls (Table 1). Factors
ontributory to death or premature sacriﬁce were either of age-
elated origin (e.g. chronic renal disease, thrombo-endocarditis)
nd/or a result of poor clinical condition in tumor-bearing (e.g. pitu-
tary adenoma of pars distalis, various soft tissue tumors) animals.
here were no factors contributory to death that could be related
o treatment with the test article. Interestingly, while there was no
ffect on longevity, there was a statistically signiﬁcant decreased in
ean survival in high dose (3.0 mg/kg) females (80.4 weeks) versus
ontrols (94.5 weeks) speciﬁcally among decedents..3. Main study parameters
Hind limb paralysis was present in 12 of 50 high dose (3.0 mg/kg)
ale rats starting at test week 79. Hind limb paralysis was  notpresent in females. Body weight was  reduced by up to 11% in high-
dose males and up to 13% in high-dose females starting between 83
and 86 weeks on study with slightly reduced body weight and body
weight gain at study termination. No test article-related changes in
food or water consumption, ophthalmological ﬁndings, or auditory
changes were present in main study rats. Calculation of acryla-
mide intake via drinking water conﬁrmed that achieved dose levels
were obtained and test article analyses were within 91 and 106%
of nominal concentrations during the course of the study.
3.4. Macroscopic post mortem ﬁndings and organ weights
The only treatment-related macroscopic change was  an increase
in mammary gland enlargements in 21 of 50 high dose females
versus 12 of 50 in control females. No test article-related changes
in absolute or relative organ weights were present at the interim
or ﬁnal dissections.
3.5. Histopathology
Non-neoplastic lesions related to treatment were present only
in rats at the terminal 104-week dissection. At this interval adrenal
cortical vacuolation was present in high-dose (3.0 mg/kg) females
(Table 2). Adrenal cortical vacuolation was represented by a dis-
crete focal change comprised of enlarged, vacuolated cells with
a mixture of clear and pale pink wispy cytoplasm and a cen-
trally located condensed nucleus. Adrenal cortical vacuolation is
an age-associated change common in rats (Laast et al., 2014). Some
vacuolated focal lesions were associated with a few hypertrophied
cells with homogeneous pink cytoplasm within the same focal
lesion. Hemorrhage was present in occasional focal vacuolated
lesions.
Hind limb skeletal muscle myopathy, sciatic nerve neurop-
athy, and spinal cord degeneration were present in both sexes
(Table 2). Histopathological ﬁndings in hind limb skeletal mus-
cle are consistent with a basic process of segmental muscle ﬁber
degeneration with progression to necrosis and accompanied by
repair. A constellation of changes including degeneration, necrosis,
mixed inﬂammatory cell response to degeneration and necro-
sis, and repair identiﬁed by increased sarcolemma nuclei was
identiﬁed in most cases. Muscle ﬁber atrophy and interstitial ﬁbro-
sis was  present in only a few cases.
The increased incidence of neuropathy was  present in sciatic
nerves from groups 3 and 4 males and group 4 females. Changes
in affected rats consisted of axonal degeneration with localized
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Table  3
Target tissue tumors in Wistar Han rat 2-year dose–water carcinogenicity study of
acrylamide.
Dose
(mg/kg/day)
Male Female
0 0.5 1.5 3 0 0.5 1.5 3
Group size 50 50 50 50 50 50 50 50
Tissue and diagnosis
Thyroid
Follicular cell
adenoma
1  11** 10** 9* 0 3 9** 14**
Follicular cell
adenocarcinoma
0  1 1 8** 3 3 3 9
Follicular cell
adenoma and/or
adenocarcinoma
1 11a,** 11** 17** 3 6 11a,** 22a,**
Mammary gland
Fibroadenoma 6 9 12 15*
Adenoma 0 0 0 1
Adenocarcinoma 7b 6 4 8b
Adenoma and/or
adenocarcinoma
7b 6 4 9b
* p < 0.05.
** p < 0.01.
a One rat had a follicular cell adenoma and a follicular cell carcinoma in the
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Table 4
Histological observations on testes and epididymides of Wistar Han  rats in a 2-year
carcinogenicity study.
Dose 0 mg/kg 0.5 mg/kg 1.5 mg/kg 3.0 mg/kg
carcinogenicity studies did not occur in the present study, reﬂect-ontralateral thyroid gland.
b Includes one adenocarcinoma arising in a ﬁbroadenoma.
ragmentation of neuroﬁbers, loss of myelin, and inﬂammatory cell
nﬁltrates, occasionally accompanied by cholesterol clefts and giant
ells. Spinal cord vacuolar degeneration and/or increased cell den-
ity representative of gliosis was present in 18% of group 4 males
nd at 4 to 8% in groups 3 and 4 females, respectively. These changes
ere minimal and present in the dorsal column of one of three
pinal cord cross sections.
A variety of other non-neoplastic spontaneous lesions typical for
istar Han rats were equally present among treated and control
roups.
Treatment-related neoplastic lesions were present in female
ammary glands and in male and female thyroid glands in the
resent study (Table 3). Mammary ﬁbroadenomas were increased
n group 3 (12/50) and group 4 (15/50) females versus control (6/50)
emales attaining statistical signiﬁcance (p = 0.0479) for group 4.
he majority of the ﬁbroadenomas were present in rats surviving
o the 24-month terminal dissection. For the terminal sacriﬁced
nimals speciﬁcally this was 11/37 in group 4 versus 5/37 in group
, not attaining statistical signiﬁcance for this observation.
A dose-related increase in thyroid follicular cell neoplasms was
resent in all dosed male groups and in the mid  and high dose
emale groups (Table 3). The majority of the neoplasms were fol-
icular cell adenomas with a few follicular cell adenocarcinomas in
he high dose males and females. With only a very few exceptions,
hese neoplasms were present at the terminal 24-month dissection
nterval. Follicular cell hyperplasia was equally present at a low
requency in all groups. The morphological features of both follicu-
ar cell adenomas and adenocarcinomas were typical of previously
ublished reports (Rosol et al., 2013; Johnson et al., 1986; Friedman
t al., 1995; Wall, 2005). A spectrum of other tumors reﬂective
f spontaneous background responses in chronic rat studies was
bserved in the present study.
While in each of the previous studies in Fischer 344 rats,
esotheliomas of the tunica vaginalis testes were observed, none
ere seen in this study (Table 4). Similarly, there was only one
eydig cell tumor in the testes. This is clearly a strain difference
etween the Fischer 344 rat and the Wistar Han rat. Similarly,
ther possible treatment-related neoplasia identiﬁed in previous
ischer 344 rat carcinogenicity studies, including clitoral gland car-
inomas, cardiac schwannomas, islet cell adenomas, and oral cavityNumber examined 50 14 15 50
Leydig cell tumors 0 0 1 0
Tunica vaginalis mesotheliomas 0 0 0 0
papillomas and carcinomas did not occur in the present Wistar Han
study.
4. Discussion
In contrast to prior chronic rat toxicity and carcinogenicity stud-
ies with acrylamide, this study included in utero exposure, use of
a Wistar Han rat stock, and included a high dose of 3.0 mg/kg/day
in both sexes. There was  excellent survival in all groups with no
treatment-related toxicity present at a 12- and 18-month interim
dissection. Hind limb weaknesses in high dose males after the 18-
month dissection and decreased body weight gain in both sexes at
the high dose are clinical indications of having achieved a suitably
high dose.
Non-neoplastic changes including sciatic nerve nephropathy,
spinal cord degeneration, and hind limb myopathy have been
reported previously in acrylamide studies (Burek et al., 1980; Shipp
et al., 2006) and were expected ﬁndings in the present study.
Adrenal cortical vacuolation represents a common age-associated
change in rats (Laast et al., 2014) and appears to have been exacer-
bated in the high dose females in the present study.
Focal adrenal cortical vacuolation was  increased in high dose
female rats in the present study. Adrenal cortical vacuolation is
commonly seen in aged rats and is a focal degenerative change
most frequently seen in the zona fasciculata (Laast et al., 2014).
It occurred late in this study, being seen primarily in the 24-month
terminal dissection rats. There was  no evidence of other progres-
sive degenerative cortical lesions in rats with focal adrenal cortical
vacuolation. It has been diagnosed as lipoid hyperplasia (Greaves,
2012) and may  represent a residual change following focal adrenal
cortical hyperplasia (Hamlin and Banas, 1990). Other explanations
for its occurrence postulate altered steroidal homeostasis (Rosol
et al., 2013). An exact cause for its exacerbation in mid- and high-
dose female rats in the present study is unknown.
Spinal cord degeneration and gliosis and sciatic nerve neurop-
athy are consistent with previous reports of neurological effects
of high doses of acrylamide (Burek et al., 1980; Edwards and
Parker, 1977; O’Shaughnessy and Losos, 1986). The skeletal muscle
changes noted in the present study are not clearly associated with
sciatic nerve neuropathy. Only ﬁfty percent of the high dose male
rats with hind limb skeletal muscle degeneration/necrosis also had
sciatic nerve neuropathy. In all other groups there was no associa-
tion of hind limb myopathy and sciatic neuropathy or between hind
limb myopathy and spinal cord degeneration/gliosis in any group.
The lack of correlation between spinal cord and sciatic neuropathy
with hind limb myopathy is indication that the muscle changes are
not neurogenic in origin.
Treatment-related neoplastic changes in acrylamide-treated
rats present at the 104-week terminal sacriﬁce included mammary
gland ﬁbroadenomas and thyroid follicular neoplasms. These same
tumor target tissues (Table 5) have been reported in prior carcino-
genicity studies in Fischer 344 rats (Johnson et al., 1986; Friedman
et al., 1995; Beland et al., 2013). The development of tunica
vaginalis mesotheliomas (TVMs) seen in previous acrylamideing the known speciﬁc susceptibility of the Fischer 344 rat to Leydig
cell tumors and the secondary induction of TVMs (Shipp et al., 2006;
Maronpot et al., 2009).
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Table  5
Summary of treatment-related tumor responses in conventional two-year carcinogenicity studies of acrylamide.
Test animal Male tumor responses Female tumor responses Reference
(F344 Rat Charles River)  Thyroid follicular cell adenoma
  Testicular mesothelioma
 Adrenal pheochromocytoma, benign
 Thyroid follicular cell adenoma or carcinoma
 Mammary gland–benign tumors (mixed)
 Oral cavity papilloma
 Uterine adenocarcinoma
 Clitoral gland adenoma
  Pituitary adenoma
Johnson et al. (1986)
(F344 Rat Charles River)  Thyroid follicular cell adenoma
  Testicular mesothelioma
 Thyroid follicular cell adenoma
  Mammary gland ﬁbroadenoma
Friedman et al. (1995)
F344/N (Nctr) rat  Thyroid follicular cell carcinoma
  Cardiac schwannomas
 Testicular mesothelioma
 Pancreatic islet cell adenoma
 Mammary gland ﬁbroadenoma
 Clitoral gland carcinoma
  Oral cavity papilloma or carcinoma
 Skin ﬁbroma or sarcoma
Beland et al. (2013)
RccHan.WIST rat  Thyroid follicular cell adenoma and
carcinoma
 Thyroid follicular cell adenoma
  Mammary gland ﬁbroadenoma
Current study
B6C3F1/Nctr mouse  Harderian gland adenoma
 Lung alveolar/bronchiolar adenoma
 Forestomach squamous cell
papilloma
 Harderian gland adenoma
 Lung alveolar/bronchiolar adenoma
 Mammary gland adenoacanthoma
 Mammary gland adenocarcinoma
Beland et al. (2013)
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mMammary gland ﬁbroadenomas have been reported in pre-
ious acrylamide rat carcinogenicity studies (Table 5). Rat
ammary gland ﬁbroadenomas are typically not considered
recursors of malignant mammary adenocarcinomas, although
denocarcinomas rarely arise within ﬁbroadenomas (Rudmann
t al., 2012). It is traditionally accepted that the leutotrophic effect
f age-associated prolactinemia is causative of rat ﬁbroadenomas
nd that this mode of action is not relevant to women where pro-
actin is not leutotrophic (Neumann, 1991; Ben-Jonathan et al.,
008). Despite some emerging evidence that increased prolactin
ay be relevant to human breast cancer (Harvey, 2011), in the
bsence of an increase in malignant mammary gland neoplasia, it is
ikely that an independent increase in rat mammary ﬁbroadenomas
as limited relevance to human cancer risk. The overall incidence of
ammary gland ﬁbroadenomas in females in the present study was
ot statistically signiﬁcant and is within published control ranges
or Wistar rats (Harleman et al., 2012; Tucker, 1997; Hooks et al.,
008; Poteracki and Walsh, 1998).
Thyroid follicular cell neoplasms were late occurring and with-
ut an associated increase in follicular cell hyperplasia. Similar
ollicular cell neoplastic responses (Table 5) have been documented
n previously conducted acrylamide carcinogenicity studies in
ischer 344 rats (Johnson et al., 1986; Friedman et al., 1995; Beland
t al., 2013). Thyroid follicular changes are associated with rat-
peciﬁc thyroid hormone synthesis, transport and metabolism that
iffer signiﬁcantly from thyroid follicular cell hormonal physi-
logy in man  (Capen, 1997; Alison et al., 1994). As opposed to
umans, rats are uniquely susceptible to development of thyroid
ollicular cell tumors because of low afﬁnity thyroxin binding to
lbumin and 10-fold shorter half-life of T3 and T4 compared to
umans (Alison et al., 1994). Consequently, induction of follicu-
ar cell neoplasms in chronic rat studies is likely a reﬂection of a
pecies-speciﬁc susceptibility associated with hormonal dysregu-
ation. Interestingly, based on a 14-day study with 2.5 mg/kg/day,
ormonal deregulation as a plausible mechanism for thyroid fol-
icular neoplasia in acrylamide treated rats was not supported
Bowyer et al., 2008). However, a role for hormonal dysregula-
ion affecting the pituitary-thyroid axis and the rat-speciﬁc thyroid
ormonal milieu is generally accepted as an explanation for follic-
lar cell neoplasia in rat carcinogenicity studies (Capen and Martin,
989; Capen, 1997; Neumann, 1991; Khan et al., 1999; Alison et al.,
994) and, as such, is a rat-speciﬁc response.
There was evidence of thyroid stimulation 7 days after treat-
ent with acrylamide as measured by morphometric decrease in Ovarian granulosa cell tumor
 Skin sarcoma
colloid size and increase of follicular cell height (Khan et al., 1999).
In Sprague Dawley rats, acrylamide lowers T3 and T4 at 8 weeks
after treatment (Hamdy et al., 2012). Acrylamide increased DNA
synthesis in thyroids at 7, 14 and 28 days of treatment in both
Sprague Dawley rats and Fischer 344 rats as measured by 7 days of
bromodeoxyuridine treatment by minipump (Lafferty et al., 2004).
However, in a different study following14 days of acrylamide treat-
ment, there was a precipitous drop in Ki-67 protein, a less sensitive
marker for proliferation (Bowyer et al., 2008). A modest decrease in
T4 was  also noted in this study and the authors suggested that an
increase in deiodinase expression might account for this effect. An
increase in deiodinase would be expected to raise the oxidation lev-
els in thyroid causing oxidative stress (Yousef and El-Demerdash,
2006). Similarly, a correlation of lowered glutathione levels has
been correlated with oxidative DNA damage in HEPG2 cells exposed
to acrylamide (Jiang et al., 2007). In that study, oxidative damage to
DNA was  caused by intracellular ROS and glutathione depletion. At
pnd 90 and 120 there was  a 4 fold increase in reverse T3 suggesting
an alternate route of thyroxin metabolism (data not shown).
Another possible explanation for rat thyroid carcinogenicity is a
direct action on thyroid DNA. Acrylamide is a weak mutagen, active
at high doses (Manjanatha et al., 2006). At doses used in this current
study, however, acrylamide mutagenicity is likely below the muta-
genic threshold. Mutagenicity has been modeled by Allen using
categorical regression (Allen et al., 2005). A BMD10 of 43 mg/kg/day
was reported in this study. A threshold of >4 mg/kg/day has been
found in the micronucleus assay in rats (Zeiger et al., 2009).
One of the primary purposes for conducting yet another two-
year rat carcinogenicity study of acrylamide was to determine if
the prior identiﬁcation of tunica vaginalis mesotheliomas (TVMs)
is directly representative of a human health hazard, or, rather, is
a consequence of a speciﬁc susceptibility of the Fischer 344 rat
to development of TVMs. The occurrence of TVMs in Fischer 344
rats is causally linked to their high incidence of Leydig cell tumors
and altered steroidogenesis (Alison et al., 1994; Shipp et al., 2006;
Maronpot et al., 2009). In the present study in Wistar Han male
rats, there were no TVMs diagnosed and only one Leydig cell tumor
was seen in a mid-dose rat (Table 4). Consequently, a plausible
mode of action for the TVMs seen in the two  previous acrylamide
two-year rat studies is related to dysregulation of the testicular
hormonal milieu and the physical effect of the high incidence of
Leydig cell tumors—both effects speciﬁc to Fischer 344 rats. Evi-
dence for dysregulation of the testicular hormonal milieu has been
previously reported (Shipp et al., 2006; Hamdy et al., 2012). Other
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ossible treatment-related neoplasia identiﬁed in previous rat
arcinogenicity studies including marginal increases in clitoral
land carcinomas, cardiac schwannomas, islet cell adenomas, and
ral cavity papillomas and carcinomas did not occur in the present
tudy. The occurrence of these marginal tumor responses in differ-
nt tissues carry similar concerns regarding relevance as TVMs and
heir assessment in terms of human health risk is best dealt with
n a weight-of-evidence approach to risk assessment.
In the present study the observed tumor responses were limited
o the thyroid and mammary glands. Both of these target tissue
umor responses have rat-speciﬁc modes of action suggesting less
ikelihood of human cancer risk than previously estimated.
In conclusion, a two-year carcinogenicity study conducted in
istar Han rats beginning with in utero exposure had excellent
urvival with clear indication that the 3.0 mg/kg/day high dose was
onsistent with a maximum tolerated dose. The study resulted in
 statistically signiﬁcant increased incidence of thyroid follicular
eoplasms in males and females and in a non-statistically signiﬁ-
ant increase in mammary ﬁbroadenomas in females. In addition,
vidence of axonal degeneration and hind limb weakness were
resent in high dose males and females. The absence of TVMs
n the present study indicates that their previous documentation
n rat carcinogenicity studies is a Fischer 344 male rat speciﬁc
esponse. In addition, epidemiologic studies of dietary acrylamide
ntake have failed to demonstrate an increased risk of cancer for
uman (Lipworth et al., 2012).
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